4 research outputs found
Glycoproteomics: Identifying the Glycosylation of Prostate Specific Antigen at Normal and High Isoelectric Points by LC–MS/MS
Prostate
specific antigen (PSA) is currently used as a biomarker
to diagnose prostate cancer. PSA testing has been widely used to detect
and screen prostate cancer. However, in the diagnostic gray zone,
the PSA test does not clearly distinguish between benign prostate
hypertrophy and prostate cancer due to their overlap. To develop more
specific and sensitive candidate biomarkers for prostate cancer, an
in-depth understanding of the biochemical characteristics of PSA (such
as glycosylation) is needed. PSA has a single glycosylation site at
Asn69, with glycans constituting approximately 8% of the protein by
weight. Here, we report the comprehensive identification and quantitation
of N-glycans from two PSA isoforms using LC–MS/MS. There were
56 N-glycans associated with PSA, whereas 57 N-glycans were observed
in the case of the PSA-high isoelectric point (pI) isoform (PSAH).
Three sulfated/phosphorylated glycopeptides were detected, the identification
of which was supported by tandem MS data. One of these sulfated/phosphorylated
N-glycans, HexNAc5Hex4dHex1s/p1 was identified in both PSA and PSAH
at relative intensities of 0.52 and 0.28%, respectively. Quantitatively,
the variations were monitored between these two isoforms. Because
we were one of the laboratories participating in the 2012 ABRF Glycoprotein
Research Group (gPRG) study, those results were compared to that presented
in this study. Our qualitative and quantitative results summarized
here were comparable to those that were summarized in the interlaboratory
study
Computational Framework for Identification of Intact Glycopeptides in Complex Samples
Glycosylation is an important protein
modification that involves
enzymatic attachment of sugars to amino acid residues. Understanding
the structure of these sugars and the effects of glycosylation are
vital for developing indicators of disease development and progression.
Although computational methods based on mass spectrometric data have
proven to be effective in monitoring changes in the glycome, developing
such methods for the glycoproteome are challenging, largely due to
the inherent complexity in simultaneously studying glycan structures
with their corresponding glycosylation sites. This paper introduces
a computational framework for identifying intact N-linked glycopeptides,
i.e. glycopeptides with N-linked glycans attached to their glycosylation
sites, in complex proteome samples. Scoring algorithms are presented
for tandem mass spectra of glycopeptides resulting from collision-induced
dissociation (CID), higher-energy C-trap dissociation (HCD), and electron
transfer dissociation (ETD) fragmentation modes. An empirical false-discovery
rate estimation method, based on a target-decoy search approach, is
derived for assigning confidence. The power of our method is further
enhanced when multiple data sets are pooled together to increase identification
confidence. Using this framework, 103 highly confident N-linked glycopeptides
from 53 sites across 33 glycoproteins were identified in complex human
serum proteome samples using conventional proteomic platforms with
standard depletion of the 7-most abundant proteins. These results
indicate that our method is ready to be used for characterizing site-specific
protein glycosylation in complex samples
Characterization of the Glycosylation Site of Human PSA Prompted by Missense Mutation using LC–MS/MS
Prostate
specific antigen (PSA) is currently used as a diagnostic
biomarker for prostate cancer. It is a glycoprotein possessing a single
glycosylation site at N69. During our previous study of PSA N69 glycosylation,
additional glycopeptides were observed in the PSA sample that were
not previously reported and did not match glycopeptides of impure
glycoproteins existing in the sample. This extra glycosylation site
of PSA is associated with a mutation in KLK3 genes. Among single nucleotide
polymorphisms (SNPs) of KLKs families, the rs61752561 in KLK3 genes
is an unusual missense mutation resulting in the conversion of D102
to N in PSA amino acid sequence. Accordingly, a new N-linked glycosylation
site is created with an N102MS motif. Here we report the first qualitative
and quantitative glycoproteomic study of PSA N102 glycosylation site
by LC–MS/MS. We successfully applied tandem MS to verify the
amino acid sequence possessing N102 glycosylation site and associated
glycoforms of PSA samples acquired from different suppliers. Among
the three PSA samples, HexNAc2Hex5 was the predominant glycoform at
N102, while HexÂNAc4ÂHex5ÂFuc1ÂNeuÂAc1 or
HexÂNAc4ÂHex5ÂFuc1ÂNeuÂAc2 was the primary
glycoforms at N69. D102 is the first amino acid of “kallikrein
loop”, which is close to a zinc-binding site and catalytic
triad. The different glycosylation of N102 relative to N69 might be
influenced by the close vicinity of N102 to these functional sites
and steric hindrance
Automated Glycan Sequencing from Tandem Mass Spectra of N‑Linked Glycopeptides
Mass spectrometry
has become a routine experimental tool for proteomic
biomarker analysis of human blood samples, partly due to the large
availability of informatics tools. As one of the most common protein
post-translational modifications (PTMs) in mammals, protein glycosylation
has been observed to alter in multiple human diseases and thus may
potentially be candidate markers of disease progression. While mass
spectrometry instrumentation has seen advancements in capabilities,
discovering glycosylation-related markers using existing software
is currently not straightforward. Complete characterization of protein
glycosylation requires the identification of intact glycopeptides
in samples, including identification of the modification site as well
as the structure of the attached glycans. In this paper, we present
GlycoSeq, an open-source software tool that implements a heuristic
iterated glycan sequencing algorithm coupled with prior knowledge
for automated elucidation of the glycan structure within a glycopeptide
from its collision-induced dissociation tandem mass spectrum. GlycoSeq
employs rules of glycosidic linkage as defined by glycan synthetic
pathways to eliminate improbable glycan structures and build reasonable
glycan trees. We tested the tool on two sets of tandem mass spectra
of N-linked glycopeptides cell lines acquired from breast cancer patients.
After employing enzymatic specificity within the N-linked glycan synthetic
pathway, the sequencing results of GlycoSeq were highly consistent
with the manually curated glycan structures. Hence, GlycoSeq is ready
to be used for the characterization of glycan structures in glycopeptides
from MS/MS analysis. GlycoSeq is released as open source software
at https://github.com/chpaul/GlycoSeq/